CENTERVILLE, MA � November 10, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's ViraTech UV-400 air purifier technology is featured during "Designing Spaces-Innovations for a Healthy Home this Holiday Season," scheduled to air on Women's Entertainment (WeTV) this Friday, November 12th, at 9:30 am, EST, and again at the same hour on Sunday the 14th and Monday the 15th.
"I was very excited to participate on the show, particularly with Dr. Dennis Rosen, a Director of our Company and one of the foremost Pediatricians in the country today, as well as a real advocate for issues affecting children's health," said Jack Lennon, President of UV Flu Technology. "We hope to educate the public on the dangers associated with poor indoor air quality at every opportunity, as we believe it contributes to tens of thousands of deaths and billions of dollars of health care and lost work expenditures every year. We also wanted to inform and educate the public of the hazards posed though the use of existing filter based products on the market today that can cause serious illness if the filters or the electrostatic plates are not changed or cleaned on a constant basis."
"Our ViraTech UV-400 was developed in part as a response to the filter issue as it has no filters to change or plates to clean and kills airborne bacteria and other organic contaminants for years with virtually no maintenance. As Dr. Rosen states on the show, Doctors have become reluctant to recommend air purifiers principally because the public was found to not regularly maintain their filter products as required, which led to many of their patients suffering from additional symptoms and increased instances of illness. Our product overcomes these shortcomings and that is why Designing Spaces thought it would be the perfect product to feature in order to help keep families healthy over the Holidays, and far into the future," said Mr. Lennon.
For those who miss the television broadcast, the segment will available for viewing next week at: www.uvflutech.com.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Wednesday, November 10, 2010
Monday, November 8, 2010
Biotech/Healthcare News: UV Flu Technologies, (UVFT.OB) Begins Shipments of Air Purifier to European Distributor
CENTERVILLE, MA � November 8, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) reports that shipments of its ViraTech UV-400 Air Purifier to its new European distributor Societe' Nema Citizen of Paris, France have commenced.
Societe' Nema Citizen (www.citizenfrance.com) is the largest distributor of Citizen Brand electronics in France, and also features a growing inventory of health and medical-related products available for distribution to retailers throughout much of Western Europe. The Company is well established and is providing an aggressive strategy designed to introduce the UV-400 to an existing consumer base utilizing extensive regional relationships and proven market penetration techniques.
"Early positive feedback supports our view that this order will be followed shortly with significant replenishment requests on an ongoing basis as we head into the winter cold and flu months," stated Jack Lennon, President of UV Flu Technologies. "Much of our initial shipment is slated for use as demonstration products specifically targeting fifty major catalog re-sellers. The distributor further supports these introductory efforts by offering a strong internet presence combined with a sizeable and knowledgeable sales force spread across the continent."
"We believe the European marketplace offers exceptional opportunities for us," said Mr. Lennon. "Europe has had incredible problems with MRSA, and other HAI's, or Hospital Associated Infections, which are bacterial strains that have grown impervious to antibiotics. In Wales recently, an outbreak of Legionnaires Disease brought the problem of poor air quality back as front page news. This disease is still widespread around the world, but experts believe it is usually misdiagnosed as pneumonia. The ViraTech UV-400 kills many of these types of airborne contaminants thereby minimizing their ability to spread, so we believe we can easily help reverse the possibility of dramatic increases in some of the most common, yet potentially deadly situations," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Societe' Nema Citizen (www.citizenfrance.com) is the largest distributor of Citizen Brand electronics in France, and also features a growing inventory of health and medical-related products available for distribution to retailers throughout much of Western Europe. The Company is well established and is providing an aggressive strategy designed to introduce the UV-400 to an existing consumer base utilizing extensive regional relationships and proven market penetration techniques.
"Early positive feedback supports our view that this order will be followed shortly with significant replenishment requests on an ongoing basis as we head into the winter cold and flu months," stated Jack Lennon, President of UV Flu Technologies. "Much of our initial shipment is slated for use as demonstration products specifically targeting fifty major catalog re-sellers. The distributor further supports these introductory efforts by offering a strong internet presence combined with a sizeable and knowledgeable sales force spread across the continent."
"We believe the European marketplace offers exceptional opportunities for us," said Mr. Lennon. "Europe has had incredible problems with MRSA, and other HAI's, or Hospital Associated Infections, which are bacterial strains that have grown impervious to antibiotics. In Wales recently, an outbreak of Legionnaires Disease brought the problem of poor air quality back as front page news. This disease is still widespread around the world, but experts believe it is usually misdiagnosed as pneumonia. The ViraTech UV-400 kills many of these types of airborne contaminants thereby minimizing their ability to spread, so we believe we can easily help reverse the possibility of dramatic increases in some of the most common, yet potentially deadly situations," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Commences Shipments of UV-400 Bacteria Killing Air Purifier to Europe
CENTERVILLE, MA � November 8, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that shipments of its ViraTech UV-400 Air Purifier to its new European distributor Societe' Nema Citizen of Paris, France have commenced.
Societe' Nema Citizen (www.citizenfrance.com) is the largest distributor of Citizen Brand electronics in France, and also features a growing inventory of health and medical-related products available for distribution to retailers throughout much of Western Europe. The Company is well established and is providing an aggressive strategy designed to introduce the UV-400 to an existing consumer base utilizing extensive regional relationships and proven market penetration techniques.
"Early positive feedback supports our view that this order will be followed shortly with significant replenishment requests on an ongoing basis as we head into the winter cold and flu months," stated Jack Lennon, President of UV Flu Technologies. "Much of our initial shipment is slated for use as demonstration products specifically targeting fifty major catalog re-sellers. The distributor further supports these introductory efforts by offering a strong internet presence combined with a sizeable and knowledgeable sales force spread across the continent."
"We believe the European marketplace offers exceptional opportunities for us," said Mr. Lennon. "Europe has had incredible problems with MRSA, and other HAI's, or Hospital Associated Infections, which are bacterial strains that have grown impervious to antibiotics. In Wales recently, an outbreak of Legionnaires Disease brought the problem of poor air quality back as front page news. This disease is still widespread around the world, but experts believe it is usually misdiagnosed as pneumonia. The ViraTech UV-400 kills many of these types of airborne contaminants thereby minimizing their ability to spread, so we believe we can easily help reverse the possibility of dramatic increases in some of the most common, yet potentially deadly situations," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Societe' Nema Citizen (www.citizenfrance.com) is the largest distributor of Citizen Brand electronics in France, and also features a growing inventory of health and medical-related products available for distribution to retailers throughout much of Western Europe. The Company is well established and is providing an aggressive strategy designed to introduce the UV-400 to an existing consumer base utilizing extensive regional relationships and proven market penetration techniques.
"Early positive feedback supports our view that this order will be followed shortly with significant replenishment requests on an ongoing basis as we head into the winter cold and flu months," stated Jack Lennon, President of UV Flu Technologies. "Much of our initial shipment is slated for use as demonstration products specifically targeting fifty major catalog re-sellers. The distributor further supports these introductory efforts by offering a strong internet presence combined with a sizeable and knowledgeable sales force spread across the continent."
"We believe the European marketplace offers exceptional opportunities for us," said Mr. Lennon. "Europe has had incredible problems with MRSA, and other HAI's, or Hospital Associated Infections, which are bacterial strains that have grown impervious to antibiotics. In Wales recently, an outbreak of Legionnaires Disease brought the problem of poor air quality back as front page news. This disease is still widespread around the world, but experts believe it is usually misdiagnosed as pneumonia. The ViraTech UV-400 kills many of these types of airborne contaminants thereby minimizing their ability to spread, so we believe we can easily help reverse the possibility of dramatic increases in some of the most common, yet potentially deadly situations," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Friday, November 5, 2010
Q&A Interview With Pharmaceutical Company, BioSante Pharmaceuticals (NASDAQ: BPAX)
POINT ROBERTS, WA - November 5, 2010 (Investorideas.com newswire, www.biotechindustrystocks.com) www.investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, presents a Q&A interview with BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
Mr. Stephen M. Simes, President and C.E.O. of BioSante Pharmaceuticals, discusses recent developments with its lead product in Phase III, LibiGel (testosterone gel) in addition to GVAX Pancreas Vaccine in Phase 2.
Q&A Excerpt:
Q: Investorideas.com
Your company just recently announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events by its independent Data Monitoring Committee (DMC). Can you give investors insight into the study, the subjects and the type of data collected?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes. We currently are conducting three Phase III LibiGel clinical studies, one of which is a very important cardiovascular events and breast cancer safety study to which you refer. We now have enrolled over 2,500 women into this study and to date the safety of LibiGel looks excellent. The rate of cardiovascular events that have been reported in the study is significantly lower than was predicted for this population of women, and the rate of breast cancer reported is close to predicted. Our objective is to show the safety of LibiGel in the treatment of female sexual dysfunction for which there is no FDA approved product today. We believe we are doing that.
Full interview: http://www.investorideas.com/CO/BPAX/news/11021.asp
About BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)
Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/
Visit company website www.biosantepharma.com.
Get stock alerts and news from BioSante (NASDAQ:BPAX) and other stocks on Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com is a leading global investor and industry research resource portal specialized in sector investing.
Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (three thousand per month). Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of Investor Ideas . http://www.investorideas.com/About/Disclaimer.asp
Forward-Looking Statements
This news release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market acceptance, size and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this presentation speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For info about BioSante Contact:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
Investorideas.com:
800-665-0411
cvanzant@investorideas.com
Mr. Stephen M. Simes, President and C.E.O. of BioSante Pharmaceuticals, discusses recent developments with its lead product in Phase III, LibiGel (testosterone gel) in addition to GVAX Pancreas Vaccine in Phase 2.
Q&A Excerpt:
Q: Investorideas.com
Your company just recently announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events by its independent Data Monitoring Committee (DMC). Can you give investors insight into the study, the subjects and the type of data collected?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes. We currently are conducting three Phase III LibiGel clinical studies, one of which is a very important cardiovascular events and breast cancer safety study to which you refer. We now have enrolled over 2,500 women into this study and to date the safety of LibiGel looks excellent. The rate of cardiovascular events that have been reported in the study is significantly lower than was predicted for this population of women, and the rate of breast cancer reported is close to predicted. Our objective is to show the safety of LibiGel in the treatment of female sexual dysfunction for which there is no FDA approved product today. We believe we are doing that.
Full interview: http://www.investorideas.com/CO/BPAX/news/11021.asp
About BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)
Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/
Visit company website www.biosantepharma.com.
Get stock alerts and news from BioSante (NASDAQ:BPAX) and other stocks on Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com is a leading global investor and industry research resource portal specialized in sector investing.
Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (three thousand per month). Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of Investor Ideas . http://www.investorideas.com/About/Disclaimer.asp
Forward-Looking Statements
This news release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market acceptance, size and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this presentation speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For info about BioSante Contact:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
Investorideas.com:
800-665-0411
cvanzant@investorideas.com
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Wednesday, November 3, 2010
NASDAQ Biotech/Pharma Market Leaders; (NASDAQ:BPAX), (NASDAQ:AMGN), (NASDAQ:LIFE) Stocks to Follow for Wednesday
Visit this company: www.biosantepharma.com
Point Roberts, WA - November 3, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Snapshot featuring some of the NASDAQ�s Actively traded market leaders for today.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 3rd)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel� Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
Life Technologies Corporation (NASDAQ:LIFE) News:
Life Technologies Launches New SOLiD Sequencer to Drive Advances in Cancer Biology and Genetic Disease Research
"Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD™ Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.
Developed and manufactured with long-standing partner Hitachi High-Technologies, the 5500xl delivers on the promise of the SOLiD 4hq, which was first announced in January. Initial shipments of the 5500xl are planned for December 2010."
Full Article: http://finance.yahoo.com/news/Life-Technologies-Launches-bw-2424991704.html?x=0&.v=1
About Life Technologies Corporation (NASDAQ:LIFE)
Life Technologies Corporation (NASDAQ:LIFE - News) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
More info on BPAX:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Investor Fact Sheet update and News:
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Financial Highlights
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX (three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA - November 3, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Snapshot featuring some of the NASDAQ�s Actively traded market leaders for today.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 3rd)
- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.52, up 0.02 (1.33%)
- Amgen Inc. (NASDAQ:AMGN), trading at $57.40, up .04 (0.07%)
- Life Technologies Corporation (NASDAQ:LIFE) trading at $ 50.71, up 0.22 (0.44%)
- Dow 11,211.88 +23.16 +0.21%
- NASDAQ 2,534.96 +1.44 +0.06%
- S&P 500 1,195.23 +1.66 +0.14%
- 10 Yr Bond (%) 2.5490% -0.0450
- Oil 84.42 +0.52 +0.62%
- Gold 1,353.00 -3.40 -0.25%
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel� Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
Life Technologies Corporation (NASDAQ:LIFE) News:
Life Technologies Launches New SOLiD Sequencer to Drive Advances in Cancer Biology and Genetic Disease Research
"Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD™ Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.
Developed and manufactured with long-standing partner Hitachi High-Technologies, the 5500xl delivers on the promise of the SOLiD 4hq, which was first announced in January. Initial shipments of the 5500xl are planned for December 2010."
Full Article: http://finance.yahoo.com/news/Life-Technologies-Launches-bw-2424991704.html?x=0&.v=1
About Life Technologies Corporation (NASDAQ:LIFE)
Life Technologies Corporation (NASDAQ:LIFE - News) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
More info on BPAX:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Investor Fact Sheet update and News:
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Financial Highlights
- At September 30, 2010, BioSante had approximately $36M in cash
- Monthly burn rate of approximately $3.5M
- Financial resources to implement plan
- Late stage pharmaceutical product portfolio with significant growth potential
- LibiGel in three ongoing Phase III safety and efficacy clinical studies
- Elestrin is FDA approved and marketed in the U.S.
- Proprietary cancer vaccines in Phase II clinical trials
- Focused growth strategy
- Management's proven ability to gain FDA approval, implement plans and increase stockholder value
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:http://www.investorideas.com/Resources/Newsletter.asp
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX (three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Tuesday, November 2, 2010
Investorideas.com - NASDAQ Biotech Market Gainers; (NASDAQ:BPAX), (NASDAQ: CELG), (NASDAQ: GILD) Stocks to Watch
Investorideas.com - NASDAQ Biotech Market Gainers; (NASDAQ:BPAX), (NASDAQ: CELG), (NASDAQ: GILD) Stocks to Watch
NASDAQ Biotechnology Index Up
Point Roberts, WA –November 2, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the NASDAQ’s market gainers in today’s trading.. Gilead Sciences Inc. (NASDAQ: GILD is currently trading at $40.29, up 0.05 (0.10%) on over 3.5 million shares.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 2nd)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.52, up 0.02 (1.33%)
Celgene Corporation (NASDAQ: CELG) trading at $62.95, up 1.05 (31.70%)
Gilead Sciences Inc. (NASDAQ: GILD) trading at $ 40.29, up 0.05 (0.10%) on over 3,511,673 million shares
NASDAQ Biotechnology Index
Index Value Net Change High Low
927.10 3.15+ 931.30 923.
Market Summary
Dow 11,201.59 +76.97 +0.69%
Nasdaq 2,529.10 +24.26 +0.97%
S&P 500 1,193.75 +9.37 +0.79%
10 Yr Bond(%) 2.5940% -0.0340
Oil 84.25 +1.30 +1.57%
Gold 1,355.80 +5.60 +0.41%
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Investor Fact Sheet update and News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Financial Highlights
• At September 30, 2010, BioSante had approximately $36M in cash
• Monthly burn rate of approximately $3.5M
Investment Highlights
• Financial resources to implement plan
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Proprietary cancer vaccines in Phase II clinical trials
• Focused growth strategy
• Management’s proven ability to gain FDA approval, implement plans and increase stockholder value
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
Gilead Sciences Inc. (NASDAQ: GILD) News:
Viread® for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment
“Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection. Significantly, no resistance to Viread emerged over 192 weeks of treatment, and 10.8 percent of patients receiving Viread in Study 103 (HBeAg-positive) for four years experienced surface, or “s”, antigen (HBsAg) loss, which is a marker of the resolution of chronic HBV infection. Additional data from these studies and from Study 106 show the durable antiviral efficacy of Viread among several key patient subpopulations, including patients with high baseline viral levels, individuals of Asian descent and treatment-experienced patients. These findings are being presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2010) in Boston.”
Full Article: http://finance.yahoo.com/news/Viread-for-Hepatitis-B-bw-2871028130.html?x=0&.v=1
About Gilead Sciences, Inc:
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX (three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
NASDAQ Biotechnology Index Up
Point Roberts, WA –November 2, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the NASDAQ’s market gainers in today’s trading.. Gilead Sciences Inc. (NASDAQ: GILD is currently trading at $40.29, up 0.05 (0.10%) on over 3.5 million shares.
Biotech /Pharma Sector Trading Snapshot: (as of time of release November 2nd)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.52, up 0.02 (1.33%)
Celgene Corporation (NASDAQ: CELG) trading at $62.95, up 1.05 (31.70%)
Gilead Sciences Inc. (NASDAQ: GILD) trading at $ 40.29, up 0.05 (0.10%) on over 3,511,673 million shares
NASDAQ Biotechnology Index
Index Value Net Change High Low
927.10 3.15+ 931.30 923.
Market Summary
Dow 11,201.59 +76.97 +0.69%
Nasdaq 2,529.10 +24.26 +0.97%
S&P 500 1,193.75 +9.37 +0.79%
10 Yr Bond(%) 2.5940% -0.0340
Oil 84.25 +1.30 +1.57%
Gold 1,355.80 +5.60 +0.41%
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Investor Fact Sheet update and News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Financial Highlights
• At September 30, 2010, BioSante had approximately $36M in cash
• Monthly burn rate of approximately $3.5M
Investment Highlights
• Financial resources to implement plan
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Proprietary cancer vaccines in Phase II clinical trials
• Focused growth strategy
• Management’s proven ability to gain FDA approval, implement plans and increase stockholder value
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
Gilead Sciences Inc. (NASDAQ: GILD) News:
Viread® for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment
“Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection. Significantly, no resistance to Viread emerged over 192 weeks of treatment, and 10.8 percent of patients receiving Viread in Study 103 (HBeAg-positive) for four years experienced surface, or “s”, antigen (HBsAg) loss, which is a marker of the resolution of chronic HBV infection. Additional data from these studies and from Study 106 show the durable antiviral efficacy of Viread among several key patient subpopulations, including patients with high baseline viral levels, individuals of Asian descent and treatment-experienced patients. These findings are being presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2010) in Boston.”
Full Article: http://finance.yahoo.com/news/Viread-for-Hepatitis-B-bw-2871028130.html?x=0&.v=1
About Gilead Sciences, Inc:
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX (three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Investorideas.com - Q&A Interview with BioSante Pharmaceuticals (NASDAQ: BPAX), Update on LibiGel® (testosterone gel) for the treatment of female sexual dysfunction and its Pancreatic Cancer Vaccine
Investorideas.com - Q&A Interview with BioSante Pharmaceuticals (NASDAQ: BPAX), Update on LibiGel® (testosterone gel) for the treatment of female sexual dysfunction and its Pancreatic Cancer Vaccine
Stephen M. Simes, President and CEO Discusses LibiGel (testosterone gel) in Phase III and GVAX Pancreas Vaccine in Phase II
November 2, 2010 - (Investorideas.com newswire, www.biotechindustrystocks.com)
www.InvestorIdeas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, presents the second in a series of Q&A interviews with BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
The first introductory Q&A can be found here:
http://www.investorideas.com/CO/BPAX/news/9211.asp
In this follow up, Stephen M. Simes, president and chief executive officer of BioSante Pharmaceuticals discusses recent developments with its lead product in Phase III, LibiGel (testosterone gel) in addition to GVAX Pancreas Vaccine in Phase 2.
Q: Investorideas.com
Your company just recently announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events by its independent Data Monitoring Committee (DMC). Can you give investors insight into the study, the subjects and the type of data collected?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes. We currently are conducting three Phase III LibiGel clinical studies, one of which is a very important cardiovascular events and breast cancer safety study to which you refer. We now have enrolled over 2,500 women into this study and to date the safety of LibiGel looks excellent. The rate of cardiovascular events that have been reported in the study is significantly lower than was predicted for this population of women, and the rate of breast cancer reported is close to predicted. Our objective is to show the safety of LibiGel in the treatment of female sexual dysfunction for which there is no FDA approved product today. We believe we are doing that.
Q: Investorideas.com
According to your press release, A new drug application (NDA) can be submitted after an average of 12 months of exposure with subjects followed for five years in total, including after NDA submission and potential FDA approval. BioSante’s objective is to submit the LibiGel NDA in 2011. The average time for FDA approval is six months to a year. Once approved by FDA, the drug becomes available for physicians to prescribe for patients- so the company is looking at 2012 for LibiGel to be available?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our objective is to submit the new drug application (NDA) in 2011 for a potential approval and launch in 2012. We belive LibiGel will be the first product to enter this market, notwithstanding the fact that Viagra was approved for men over 12 years ago. The time for women to have a product to trat their sexual issues has come!
Q: Investorideas.com
You recently stated , “With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD”- for investors looking at potential revenue for this product , what does this represent for the company?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
The forecast for the size of the potential market for female sexual dysfunction products varies from $2 billion up to $5 billion. The market for erectile dysfunction products like Viagra is over $2 billion just in the U.S. We believe LibiGel alone has the potential to be a $1 billion per year product.
Q: Investorideas.com
In a recent article on Seeking Alpha, discussing pancreatic cancer, your company is featured in the section “Select Pancreatic Products in Active Clinical Development”. Can you give us an overview and update on the GVAX Pancreas Vaccine, Phase 2.
Article source for reference:
http://seekingalpha.com/article/232174-amgen-celgene-and-novartis-in-the-fight-against-pancreatic-cancer?source=yahoo
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We have a full pipeline of cancer vaccines in clinic al trials. In fact there are 12 ongoing clinical trials in pancreatic cancer and breast cancer among other cancer types. Cancer vaccines represent the next wave in potential therapies for cancer patients and we hope to contribute to that wave. Data to date have been excellent.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/
Or the company website www.biosantepharma.com to learn more about BioSante.
Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech/Pharma Stocks portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech/pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (three thousand per month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Forward-Looking Statements
This news release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, future market acceptance, size and potential of LibiGel and other statements identified by words such as “will,” “potential,” “could,” “would,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this presentation speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For info about BioSante Pharmaceuticals, Inc
Contact:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com
Stephen M. Simes, President and CEO Discusses LibiGel (testosterone gel) in Phase III and GVAX Pancreas Vaccine in Phase II
November 2, 2010 - (Investorideas.com newswire, www.biotechindustrystocks.com)
www.InvestorIdeas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, presents the second in a series of Q&A interviews with BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
The first introductory Q&A can be found here:
http://www.investorideas.com/CO/BPAX/news/9211.asp
In this follow up, Stephen M. Simes, president and chief executive officer of BioSante Pharmaceuticals discusses recent developments with its lead product in Phase III, LibiGel (testosterone gel) in addition to GVAX Pancreas Vaccine in Phase 2.
Q: Investorideas.com
Your company just recently announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events by its independent Data Monitoring Committee (DMC). Can you give investors insight into the study, the subjects and the type of data collected?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes. We currently are conducting three Phase III LibiGel clinical studies, one of which is a very important cardiovascular events and breast cancer safety study to which you refer. We now have enrolled over 2,500 women into this study and to date the safety of LibiGel looks excellent. The rate of cardiovascular events that have been reported in the study is significantly lower than was predicted for this population of women, and the rate of breast cancer reported is close to predicted. Our objective is to show the safety of LibiGel in the treatment of female sexual dysfunction for which there is no FDA approved product today. We believe we are doing that.
Q: Investorideas.com
According to your press release, A new drug application (NDA) can be submitted after an average of 12 months of exposure with subjects followed for five years in total, including after NDA submission and potential FDA approval. BioSante’s objective is to submit the LibiGel NDA in 2011. The average time for FDA approval is six months to a year. Once approved by FDA, the drug becomes available for physicians to prescribe for patients- so the company is looking at 2012 for LibiGel to be available?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our objective is to submit the new drug application (NDA) in 2011 for a potential approval and launch in 2012. We belive LibiGel will be the first product to enter this market, notwithstanding the fact that Viagra was approved for men over 12 years ago. The time for women to have a product to trat their sexual issues has come!
Q: Investorideas.com
You recently stated , “With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD”- for investors looking at potential revenue for this product , what does this represent for the company?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
The forecast for the size of the potential market for female sexual dysfunction products varies from $2 billion up to $5 billion. The market for erectile dysfunction products like Viagra is over $2 billion just in the U.S. We believe LibiGel alone has the potential to be a $1 billion per year product.
Q: Investorideas.com
In a recent article on Seeking Alpha, discussing pancreatic cancer, your company is featured in the section “Select Pancreatic Products in Active Clinical Development”. Can you give us an overview and update on the GVAX Pancreas Vaccine, Phase 2.
Article source for reference:
http://seekingalpha.com/article/232174-amgen-celgene-and-novartis-in-the-fight-against-pancreatic-cancer?source=yahoo
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We have a full pipeline of cancer vaccines in clinic al trials. In fact there are 12 ongoing clinical trials in pancreatic cancer and breast cancer among other cancer types. Cancer vaccines represent the next wave in potential therapies for cancer patients and we hope to contribute to that wave. Data to date have been excellent.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/
Or the company website www.biosantepharma.com to learn more about BioSante.
Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech/Pharma Stocks portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech/pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (three thousand per month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Forward-Looking Statements
This news release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, future market acceptance, size and potential of LibiGel and other statements identified by words such as “will,” “potential,” “could,” “would,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this presentation speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For info about BioSante Pharmaceuticals, Inc
Contact:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com
Subscribe to:
Posts (Atom)